ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
14 nov. 2024 16h05 HE
|
ReShape Lifesciences Inc
Revenue Increased 16.6% in the Third Quarter of 2024 Over the Second Quarter, Representing the Third Sequential Quarter of Growth, and 6.4% Compared to the Same Period in 2023 Significant...
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
12 nov. 2024 16h05 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will...
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
12 nov. 2024 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health...
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology
11 nov. 2024 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company...
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
19 sept. 2024 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its...
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
14 août 2024 16h05 HE
|
ReShape Lifesciences Inc
Entered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Significant Reduction in Overall Operating Expenses of 45.4% in the First Half of 2024 Compared...
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
13 août 2024 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will...
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
09 juil. 2024 08h31 HE
|
ReShape Lifesciences Inc
ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger ReShape to Sell its Assets to...
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
15 mai 2024 16h05 HE
|
ReShape Lifesciences Inc
Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 ...
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
14 mai 2024 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will...